UFP Technologies, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Unaudited results; amounts below are in U.S. dollars unless stated otherwise. UFP Technologies designs and manufactures custom engineered products, with a strong focus on medical devices and packaging. It reports as one operating segment.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net sales | $100.0m | $94.3m | $197.8m | $165.6m |
| Gross profit | $29.6m | $24.3m | $58.3m | $41.5m |
| Gross margin | 29.6% | 25.8% | 29.5% | 25.0% |
| Operating income | $17.0m | $12.2m | $29.9m | $18.6m |
| Net income | $11.9m | $8.9m | $21.6m | $13.8m |
| Diluted EPS | $1.55 | $1.17 | $2.81 | $1.81 |
- Management attributed the six-month sales increase of 19.4% primarily to approximately 23.9% organic sales growth. Medical-market sales grew 15.9% in Q2 and 34.0% for the six months. Medical accounted for 86% of Q2 sales and 86% of first-half sales.
- Management attributed margin expansion mainly to higher organic volume and operating leverage, improved operating efficiencies, and price adjustments in response to input-cost inflation. Q2 SG&A was $12.3m, or 12.3% of sales, versus $12.1m, or 12.8%, a year earlier.
- Six-month operating cash flow was $10.6m, compared with cash used of $0.04m in the prior-year period. Capital expenditures were $5.0m; investing cash outflow was $4.9m. Cash increased $0.8m to $5.3m during the six months.
- At June 30, total debt was $57.0m ($23.0m revolving facility and $34.0m term loan); cash was $5.3m. The $130m credit agreement includes a $90m revolving facility and matures in December 2026. The reported borrowing rate was approximately 6.4%; the company said it was in compliance with its covenants. Standby letters of credit were approximately $0.7m.
- Current assets were $137.1m and current liabilities $53.0m. Receivables were $64.1m and inventories $63.0m, up from $55.1m and $53.5m, respectively, at year-end 2022.
Changes, unusual items, and management outlook
- Reported year-over-year comparisons include significant unusual items. Q2 2022 included a $6.2m gain on the sale of property, plant and equipment, while Q2 2023 recorded a $0.1m loss. The six-month periods show the same respective gain and loss. The 2022 periods also included $6.0m of contingent-consideration expense; 2023 included $0.2m in Q2 and $3.1m for the six months. These items affect interpretation of operating income trends.
- Other markets’ sales declined, which management attributed primarily to the July 2022 sale of the molded-fiber business. That divestiture generated a $15.7m gain in 2022, outside the periods presented here. Q2 2023 sales to markets other than medical were down 30.6% overall, while medical sales increased.
- Interest expense rose to $1.1m in Q2 and $2.0m for the six months, primarily reflecting higher interest rates. The six-month effective tax rate was 22.4%, versus 22.1%; management cited expected limits on deductions for executive compensation and noted potential tax-rate volatility from share-based compensation.
- Management plans to add manufacturing capacity and may pursue complementary acquisitions. It believes cash, expected operating cash flow, and its revolving facility will be sufficient for requirements through the next 12 months, but cautioned that future liquidity depends on operating performance and financing availability. The filing provides no specific revenue or earnings guidance.
- Key risks discussed include acquisition identification and integration, debt and covenant compliance, access to financing, execution of manufacturing efficiencies and new program launches, and uncertainty in customer demand and broader economic conditions. No material litigation or material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- How much of reported growth and margin improvement is organic and sustainable, particularly given the prior-year divestiture and the shift toward medical-market sales.
- The drivers and assumptions behind the $12.6m fair value of DAS Medical contingent consideration, future payments (up to $20m), and related measurement changes.
- Working-capital trends: receivables and inventory rose substantially, and the company cited higher late-quarter sales and inventory build/restocking as contributing factors.
- Debt capacity, interest-rate exposure, covenant headroom, and the timing of the $47m of scheduled 2026 maturities shown in the filing.
- Customer concentration: one customer represented 24.7% of Q2 revenue and 22.7% of first-half revenue; two customers represented 23.8% of gross receivables at June 30.